KR20040074795A - Cosmetic composition for preventing a wrinkles - Google Patents
Cosmetic composition for preventing a wrinkles Download PDFInfo
- Publication number
- KR20040074795A KR20040074795A KR1020030010259A KR20030010259A KR20040074795A KR 20040074795 A KR20040074795 A KR 20040074795A KR 1020030010259 A KR1020030010259 A KR 1020030010259A KR 20030010259 A KR20030010259 A KR 20030010259A KR 20040074795 A KR20040074795 A KR 20040074795A
- Authority
- KR
- South Korea
- Prior art keywords
- cosmetic composition
- wrinkles
- dicarboxy
- carnosine
- wrinkle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000037303 wrinkles Effects 0.000 title claims abstract description 38
- 239000002537 cosmetic Substances 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 108010087806 Carnosine Proteins 0.000 claims abstract description 27
- HIXYEIRACBUSON-FJXQXJEOSA-N (2s)-2-(3-aminopropanoylamino)-3-(1h-imidazol-5-yl)propanoic acid;hydrochloride Chemical compound Cl.NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 HIXYEIRACBUSON-FJXQXJEOSA-N 0.000 claims abstract description 24
- 229940070763 carnosine hydrochloride Drugs 0.000 claims abstract description 24
- 230000001153 anti-wrinkle effect Effects 0.000 claims abstract description 8
- ANRUJJLGVODXIK-UHFFFAOYSA-N 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide Chemical compound NCCC(=O)NCCC1=CN=CN1 ANRUJJLGVODXIK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 108700021352 carcinine Proteins 0.000 claims abstract description 3
- 108010035532 Collagen Proteins 0.000 abstract description 20
- 102000008186 Collagen Human genes 0.000 abstract description 20
- 229920001436 collagen Polymers 0.000 abstract description 20
- 230000015572 biosynthetic process Effects 0.000 abstract description 18
- 230000003078 antioxidant effect Effects 0.000 abstract description 14
- 238000003786 synthesis reaction Methods 0.000 abstract description 14
- 239000000126 substance Substances 0.000 abstract description 5
- ZQTUNIWBUQUKAM-UHFFFAOYSA-N [3-[2-(1h-imidazol-1-ium-4-yl)ethylamino]-3-oxopropyl]azanium;dichloride Chemical compound Cl.Cl.NCCC(=O)NCCC1=CN=CN1 ZQTUNIWBUQUKAM-UHFFFAOYSA-N 0.000 abstract description 2
- 229940033353 decarboxy carnosine hydrochloride Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000008845 photoaging Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 102100030497 Cytochrome c Human genes 0.000 description 3
- 108010075031 Cytochromes c Proteins 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- ARYRBWIHAPKTKR-UHFFFAOYSA-N 1-ethoxypropane Chemical compound CC[CH]OCC ARYRBWIHAPKTKR-UHFFFAOYSA-N 0.000 description 2
- NVJUHMXYKCUMQA-UHFFFAOYSA-N 1-ethoxypropane Chemical compound CCCOCC NVJUHMXYKCUMQA-UHFFFAOYSA-N 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- -1 Polyoxyethylene lauryl ether Polymers 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
- A61K2800/72—Hypo-allergenic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 통상의 화장료에 특정물질을 일정성분으로 함유시킴으로서 주름방지 효과 및 항산화효과를 갖는 화장료 조성물에 관한 것으로, 본 발명의 주름방지 화장료 조성물은 콜라겐 합성 능력과 항산화 효과를 가지는 하기 화학식 1The present invention relates to a cosmetic composition having an anti-wrinkle effect and an antioxidant effect by containing a specific substance in a conventional cosmetic as a certain component, the anti-wrinkle cosmetic composition of the present invention having the ability to synthesize collagen and antioxidant effect
[화학식 1][Formula 1]
의 디카르복시 카노신 하이드로클로라이드(Decarboxy Carnosine 2HCl; Carcinine)를 함유함을 특징으로 한다.It is characterized by containing a decarboxy carnosine hydrochloride (Decarboxy Carnosine 2HCl; Carcinine).
상기한 바와 같이 본 발명의 구성에 따라 디카르복시 카노신 하이드로 클로라이드를 함유한 화장료 조성물은 콜라겐의 합성을 증가시키고 항산화 작용을 가지고 있어 인체의 주름 형성을 방지 할 뿐 아니라, 피부에 대한 안전성이 우수하며, 화장료 조성물에서의 물질의 안정성도 우수하다.As described above, the cosmetic composition containing dicarboxy carnosine hydrochloride according to the composition of the present invention increases the synthesis of collagen and has an antioxidant action, which not only prevents the formation of wrinkles in the human body, but also has excellent safety for the skin. The stability of the substance in the cosmetic composition is also excellent.
Description
본 발명은 주름방지 효과를 갖는 화장료 조성물에 관한 것으로, 보다 자세하게는 통상의 화장료에 특정물질을 일정성분으로 함유시킴으로서 주름방지 효과 및 항산화 효과를 갖는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition having an anti-wrinkle effect, and more particularly to a cosmetic composition having an anti-wrinkle effect and an antioxidant effect by containing a specific substance as a certain component in a conventional cosmetic.
통상적으로 주름은 오랜 기간동안 반복되는 근육운동으로 인해 형성되는 피부의 자연스런 노화현상의 하나이다. 피부노화는 크게 자연노화 혹은 내인성 노화와 외적노화로 구분되며(E.B. Doris, 1996) 자연노화는 유전적 원인에 의한 것이므로 조절이 어려우나 외적노화는 환경적 원인에 의한 것이므로 인위적인 조절이 용이하다. 따라서 외적노화를 방지하기 위한 연구가 지속되어 왔으며, 특히 장기간 자외선 노출에 의해 진행되는 외인성 광노화에 따른 주름형성 방지에 대한 연구가 주목되고 있다.Wrinkles are one of the natural aging phenomena of the skin that are usually formed by repeated muscle movements over long periods of time. Skin aging is largely divided into natural aging or endogenous aging and external aging (E.B. Doris, 1996). Because natural aging is caused by genetic causes, it is difficult to control, but external aging is caused by environmental causes. Therefore, studies to prevent external aging have been continued, and in particular, research on preventing wrinkle formation caused by exogenous photoaging due to prolonged ultraviolet exposure has been focused.
상기한 바와 같이 외인성 광노화에 따라 형성되는 주름에는 활성산소와 여러가지 프리라디칼이 관여하며(Christina S et al, Photoaging is Associated with Protein Oxidation in Human Skin In Vivo, J Invest Dermatol 2002;118:618-625), 콜라겐의 감소와 엘라스틴의 가교결합 증가, 기질의 저하에 따른 피부의 탄력저하 등이 주원인이 된다. 또한 섬유아세포의 증식이 감소되면 콜라겐 합성이 적어지고, 이것은 외부인자에 대한 방어력의 약화로 이어져 주름생성을 촉진하게 된다. 따라서 활성산소 생성 억제와 콜라겐 합성을 촉진시킴으로써 주름방지 효과를 기대 할 수 있다.As described above, wrinkles formed by exogenous photoaging are involved with free radicals and various free radicals (Christina S et al, Photoaging is Associated with Protein Oxidation in Human Skin In Vivo, J Invest Dermatol 2002; 118: 618-625). The main causes are decreased collagen, increased elastin crosslinking, and decreased skin elasticity due to substrate degradation. In addition, decreased fibroblast proliferation decreases collagen synthesis, which leads to weakening of defense against external factors, thereby promoting wrinkle formation. Therefore, anti-wrinkle effect can be expected by promoting the generation of free radicals and collagen synthesis.
종래 피부의 주름을 개선시키는데 사용되었던 레티노이드는 레티노인산, 레티닐 아세테이트, 레티닐 팔미테이트 등 비타민 A와 그 유도체를 총칭하는 것으로 광노화를 방지하고 콜라겐 소실 억제 및 콜라겐 생합성을 촉진하는 것으로 알려져 있다(Griffiths CE, The role of retinoids in the prevention and repair of aged and photoaged skin, Clin Exp Dermatol 2001 Oct;26(7):613-8).Retinoids, which have been used to improve wrinkles of the skin, are generically known as vitamin A and derivatives thereof such as retinoic acid, retinyl acetate, retinyl palmitate, and are known to prevent photoaging, inhibit collagen loss and promote collagen biosynthesis (Griffiths CE , The role of retinoids in the prevention and repair of aged and photoaged skin, Clin Exp Dermatol 2001 Oct; 26 (7): 613-8).
그러나 콜라겐 합성 촉진물질로 잘 알려진 레티노인산의 경우 불안정하고, 피부적용시 자극, 발적 등의 안전성 문제로 사용량이 극히 제한되어 있으며 항산화작용 및 콜라겐 합성 과정에 필수적인 비타민 C는 열, 빛, 산소 등에 매우 불안정하여 대기중에 노출되거나 수용액 중에서 쉽게 산화되어 변색, 변취가 일어나는 등문제점을 갖고 있어 생체에 안전하고 콜라겐합성 촉진 효과가 좋은 원료의 개발이 절실히 요망되고 있다.However, retinoic acid, which is well known as a collagen synthesis promoter, is unstable, and its usage is extremely limited due to safety problems such as irritation and redness when applying skin, and vitamin C, which is essential for antioxidant activity and collagen synthesis, is very unstable in heat, light, oxygen Therefore, there is a problem such as discoloration and odor caused by being exposed to the air or easily oxidized in an aqueous solution, and it is urgently required to develop a raw material that is safe for living organisms and has good collagen synthesis promoting effect.
따라서, 본 발명의 목적은 상기한 종래에 피부의 주름 개선을 위해 사용되었던 물질이지니고 있던 불안전성 및 불안정성의 문제점이 없으면서 콜라겐 합성 및 항산화 효과를 가지는 새로운 물질을 제공하기 위한 것이다.Accordingly, it is an object of the present invention to provide a new material having collagen synthesis and antioxidant effects without the problems of instability and instability that were previously used for improving wrinkles of the skin.
본 발명의 또 다른 목적은 사용에 있어 안전성과 안정성이 우수하며, 콜라겐 합성 및 항산화 효과를 가지는 새로운 물질을 함유하는 주름방지 화장료 조성물을 제공하기 위한 것이다.Another object of the present invention is to provide an anti-wrinkle cosmetic composition which is excellent in safety and stability in use and contains a new substance having collagen synthesis and antioxidant effect.
이에 본 발명자들은 포유동물의 조직에 존재하며 비단백질 성분에서 찾을 수 있는 이미다졸구조를 포함하는 천연성분으로 디카르복시 카노신 하이드로클로라이드가 콜라겐 생성 및 항산화 효과가 있음을 알아내어 본 발명을 완성하기에 이르렀다.Therefore, the present inventors have found that dicarboxy carnosine hydrochloride has a collagen production and antioxidant effect as a natural component that exists in mammalian tissue and includes an imidazole structure found in non-protein components. Reached.
도 1은 본 발명에 따른 디카르복시 카노신 하이드로클로라이드의 시간에 따른 TBARS의 생성양을 나타내는 그래프이고,1 is a graph showing the amount of TBARS produced over time of dicarboxy carnosine hydrochloride according to the present invention,
도 2는 본 발명에 따른 디카르복시 카노신 하이드로클로라이드 0.1%를 함유하는 실시예 4의 시간에 따른 사이토크롬 씨(Cytochrome c)의 환원정도를 나타낸 그래프이다.Figure 2 is a graph showing the degree of reduction of cytochrome c (Cytochrome c) over time of Example 4 containing 0.1% dicarboxy carnosine hydrochloride according to the present invention.
상기 목적을 달성하기 위한 본 발명의 주름방지 화장료 조성물은;Anti-wrinkle cosmetic composition of the present invention for achieving the above object;
콜라겐 합성 능력과 항산화 효과를 가지는 하기 화학식 1Formula 1 having collagen synthesis ability and antioxidant effect
[화학식 1][Formula 1]
의 디카르복시 카노신 하이드로클로라이드(Decarboxy Carnosine 2HCl; Carcinine)를 함유함을 특징으로 한다.It is characterized by containing a decarboxy carnosine hydrochloride (Decarboxy Carnosine 2HCl; Carcinine).
본 발명의 다른 구성에 따르면, 상기 디카르복시 카노신 하이드로클로라이드는 화장료 조성물의 총중량을 기준으로 0.1 ~ 2 중량% 함유하는 것을 특징으로 한다.According to another configuration of the present invention, the dicarboxy carnosine hydrochloride is characterized in that it contains 0.1 to 2% by weight based on the total weight of the cosmetic composition.
상기 본 발명에 따른 화장료 조성물은 수상 또는 유상으로 구성 될 수 있는데, 수상은 보습제, 정제수, 2가 금속염, 친수성 비이온 계면활성제, 또는 수용성 폴리머 등의 성분을 더 함유할 수 있고, 유상은 고급 알코올, 분체, 유용성 폴리머, 세라마이드 또는 그 유도체, 콜레스테롤 또는 그 유도체 등의 성분을 더 함유할 수 있다.The cosmetic composition according to the present invention may be composed of an aqueous phase or an oil phase, and the aqueous phase may further contain components such as a moisturizer, purified water, a divalent metal salt, a hydrophilic nonionic surfactant, or a water-soluble polymer, and the oil phase may be a higher alcohol. , Powder, oil-soluble polymer, ceramide or derivatives thereof, cholesterol or derivatives thereof, and the like.
상기한 바와 같이 항산화 효과와 콜라겐 합성 억제능력을 가지는 본 발명의 디카르복시 카노신 하이드로클로라이드는 카노신을 디카르복실레이션시켜 안정화시킨 백색의 분말상 성분으로 카노신은 세포예정사 관련 질환의 예방 및 치료(특2002-0044740), 신부전증 치료(특1999-0076920), 염증성 장질환 예방 및 치료(특0180556) 등이 알려져 있고, 광보호 효과를 가지고 있는 것으로(Babizhayev MA et al. Biochemistry (Mosc) 1998 May;63(5):523-8) 알려져 있다.As described above, the dicarboxy cannosine hydrochloride of the present invention having an antioxidant effect and the ability to inhibit collagen synthesis is a white powdery component stabilized by decarboxylation of cannosine. 2002-0044740), the treatment of renal failure (especially 1999-0076920), the prevention and treatment of inflammatory bowel disease (especially 0180556), etc. are known to have a photoprotective effect (Babizhayev MA et al. Biochemistry (Mosc) 1998 May; 63 (5): 523-8) Known.
이하 본 발명을 실시예 및 실험예를 통하여 보다 자세하게 설명한다. 그러나 이들 실시예 및 실험예는 본 발명에 대한 이해를 돕기위한 것일뿐 본 발명의 범위가 하기 실시예 및 실험예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples. However, these Examples and Experimental Examples are only for the purpose of understanding the present invention, and the scope of the present invention is not limited to the following Examples and Experimental Examples.
실시예 1Example 1
하기 표 1의 구성으로 디카르복시 카노신 하이드로클로라이드를 함유하는 유연 화장수를 제조한다.To a flexible lotion containing dicarboxy carnosine hydrochloride in the configuration of Table 1 below.
실시예 2Example 2
하기 표 2의 구성으로 디카르복시 카노신 하이드로클로라이드를 함유하는 로션을 제조한다.To prepare a lotion containing dicarboxy carnosine hydrochloride in the configuration of Table 2.
실시예 3Example 3
하기 표 3의 구성으로 디카르복시 카노신 하이드로클로라이드를 함유하는 에센스를 제조한다.To prepare an essence containing dicarboxy carnosine hydrochloride in the configuration of Table 3.
실시예 4Example 4
하기 표 4의 구성으로 디카르복시 카노신 하이드로클로라이드를 함유하는 크림을 제조한다.To prepare a cream containing dicarboxy carnosine hydrochloride in the configuration of Table 4.
실험예 1Experimental Example 1
콜라겐 섬유 생합성 효과Collagen Fiber Biosynthesis Effect
섬유아세포(fibroblast W138)를 48웰(well) 플레이트에 5×104cell/well 이 되도록 하여 24시간동안 배양하였다. 상층액 제거 후 무혈청 배양배지에 농도별로 디카르복시 카노신 하이드로클로라이드를 희석하여 처리하였다. 24시간 후 각 웰의 상층액을 수집하여 프로콜라겐 타입 IC-펩타이드(Procollagen type IC-peptide; PICP)의 양을 콜라겐 섬유 생합성 측정용 키트(Procollagen Type IC-peptide EIA kit: Takara MK101)를 사용하여 450nm에서 흡광도를 측정하였다. 양성 대조군으로는 TGF-β를 사용하였고 10 ng/ml로 처리하였다.Fibroblasts (fibroblast W138) were incubated for 24 hours with 5 × 10 4 cells / well in 48 well plates. After removal of the supernatant, dicarboxylic carnosine hydrochloride was treated by diluting the serum-free culture medium by concentration. After 24 hours, the supernatant of each well was collected and the amount of procollagen type IC-peptide (PICP) was measured using a collagen fiber biosynthesis kit (Procollagen Type IC-peptide EIA kit: Takara MK101). Absorbance was measured at 450 nm. TGF-β was used as a positive control and treated at 10 ng / ml.
상기 표 5에 나타난 바와 같이 디카르복시 카노신 하이드로클로라이드는 농도의존적으로 콜라겐합성을 증가시켰다. 양성대조군으로 사용된 TGF-β의 50 ug/ml에서의 콜라겐 합성량이 118.9 ng/ml 이었다. 이와 비교해 볼때 디카르복시 카노신 하이드로클로라이드는 50 ug/ml에서 약 98%의 유의한 콜라겐 합성효과가 있음을 알 수 있었다.As shown in Table 5, dicarboxy carnosine hydrochloride increased collagen synthesis in a concentration-dependent manner. The amount of collagen synthesis at 50 ug / ml of TGF-β used as a positive control was 118.9 ng / ml. In comparison, dicarboxy carnosine hydrochloride was found to have a significant collagen synthesis effect of about 98% at 50 ug / ml.
실험예 2Experimental Example 2
항산화 효과Antioxidative effect
1) MDA 측정1) MDA measurement
본 실험은 노박(Nowak; 1991)의 방법에 의한 것으로 잔틴 옥시다제(Xanthine-Oxidase) 0.01 U/ml의 첨가로 반응을 일으켰다. 트리클로로아세트산(trichloroacetic acid, 60g/l) 1 ml를 넣어서 반응을 종결시킨 후 치오바비튜릭산(thiobarbituric acid, 10g/l) 0.5 ml을 넣고 15분동안 끓여 분석을 위한 적정 색깔을 얻었다. 처리 농도는 10 mM이었고 과산화수소를 대조군으로 532 nm에서 흡광도를 구하여 그 결과를 표 6에 나타냈다.The experiment was performed by Novak (1991), and the reaction was caused by the addition of 0.01 U / ml of Xanthine-Oxidase. The reaction was terminated by adding 1 ml of trichloroacetic acid (60 g / l), and 0.5 ml of thiobarbituric acid (10 g / l) was added thereto and boiled for 15 minutes to obtain an appropriate color for analysis. The treatment concentration was 10 mM and the absorbance at 532 nm was determined using hydrogen peroxide as a control and the results are shown in Table 6.
상기 표 6에 나타난 바와 같이 디카르복시 카노신 하이드로클로라이드는 대조군을 기준으로 약 66%의 MDA 생성 억제효과를 가지고 있음을 알 수 있다.As shown in Table 6, it can be seen that dicarboxy carnosine hydrochloride has an inhibitory effect of MDA production of about 66% based on the control group.
2) TBARS 측정(Thiobarbituric acid-reactive substances assay)2) TBARS measurement (Thiobarbituric acid-reactive substances assay)
본 실험은 바비쯔헤이예브(Babizhayev; 1989)에 의해 고안된 방법을 사용하였다. 리포좀의 과산화는 2.5 ㎕의 FeSO4와 200 uM의 아스코베이트(Ascorbate)를 첨가함으로써 시작되었고 트리클로로아세트산 15%를 함유하는 2ml의 0.25N HCl을 첨가함으로써 종료시켰다. 치오바비튜르산 0.125%를 첨가하고 15분 동안 끓인 후 식혀서 15분동안 3,000 rpm에서 원심분리하였고 상층액의 흡광도를 532 nm에서 측정하였다. 말론디알데하이드(malondialdehyde; MDA)의 표준곡선은 1,1,3,3, 테트라 에톡시프로판으로부터 얻었다. 10 mM의 디카르복시 카노신 하이드로클로라이드에의한 TBARS의 생성 억제를 측정하였다.This experiment used a method devised by Babizhayev (1989). The peroxidation of liposomes was started by adding 2.5 μl of FeSO 4 and 200 uM of ascorbate and ended by adding 2 ml of 0.25N HCl containing 15% of trichloroacetic acid. 0.125% of chiovabituric acid was added, boiled for 15 minutes, cooled and centrifuged at 3,000 rpm for 15 minutes, and the absorbance of the supernatant was measured at 532 nm. Standard curves of malondialdehyde (MDA) were obtained from 1,1,3,3 and tetra ethoxypropane. Inhibition of production of TBARS by 10 mM dicarboxy carnosine hydrochloride was measured.
도 1에서 나타난 바와 같이 10~20초 사이에 최고 산화를 보였고 디카르복시 카노신 하이드로클로라이드는 대조군과 비교하여 TBARS 생성을 감소시켰다.As shown in Figure 1 showed the highest oxidation between 10-20 seconds and dicarboxy carnosine hydrochloride reduced TBARS production compared to the control.
3) SOD유사 활성 측정3) SOD-like activity measurement
본 실험은 사람의 피부를 대신하여 돼지의 귀에서 생검하여 얻은 조직을 사용하였다(P. Dick and al. 1991). 조직을 70℃에서 70초간 가열한 후 물리적으로 표피-진피 부분을 분리 해 내었다. 실시예 4를 분리한 피부절편에 5분동안 처리하고 1% TRITON X 100 용액으로 세정하였다. UVA-UVB를 조사한 후(0.8 J/㎠), 완충액에서 잘게 부수고 1% TRITON X 100 에 희석하여 0 ℃에서 2시간동안 보관하였다. 그 후 원심분리하여 상층액을 얻었고 유사 SOD 활성을 측정하였다.This experiment used tissues obtained by biopsy from pig ears instead of human skin (P. Dick and al. 1991). The tissues were heated at 70 ° C. for 70 seconds before physically separating the epidermis-dermis. Example 4 was treated with separated skin sections for 5 minutes and washed with 1% TRITON X 100 solution. After UVA-UVB irradiation (0.8 J / cm 2), it was crushed in buffer and diluted in 1% TRITON X 100 and stored at 0 ° C. for 2 hours. The supernatant was then obtained by centrifugation and similar SOD activity was measured.
SOD 활성은 1.25 mM DTPA를 함유하는 50 mM 완충액에 10 mg skin/ ml로 된 조직액을 넣었고 100 ㎕의 잔틴옥시다제(Xanthine oxidase, 0.06 U/ml)를 첨가함으로써 반응을 시작시켰다. 25℃를 유지하는 스펙트로미터에서 싸이토크롬 씨(Cytocrome c)의 환원 속도를 550nm의 흡광도를 통해 측정하였다. 피부에 대한 보호 효과는 아래의 식에 의거하여 구하였다.SOD activity was initiated by adding 10 μl skin / ml tissue solution to 50 mM buffer containing 1.25 mM DTPA and adding 100 μl of Xanthine oxidase (0.06 U / ml). The reduction rate of cytochrome c on a spectrometer maintained at 25 ° C. was measured by absorbance at 550 nm. The protective effect on skin was calculated | required based on the following formula.
보호 효과(%)=(Irradiation 0% - Irradiation 0.1%)/(Irradiation 0% - No Irradiation) ×100Protective Effect (%) = (Irradiation 0%-Irradiation 0.1%) / (Irradiation 0%-No Irradiation) × 100
* No irradiation : 자외선 처리하지 않은 피부조직에서의 흡광도 변화, 피부조직의 자연상태에서의 SOD 유사활성을 나타냄.* No irradiation: Absorption change in non-UV treated skin tissue, SOD-like activity in natural state of skin tissue.
* Irradiation 0% : 디카르복시 카노신 하이드로클로라이드 0%를 함유한 크림의 흡광도 변화, 피부조직의 SOD 유사활성에 대한 자외선의 최고작용을 나타냄.* Irradiation 0%: Change of absorbance of cream containing 0% of dicarboxy carnosine hydrochloride, showing the best effect of ultraviolet rays on SOD-like activity of skin tissue.
* Irradiation 0.1% : 디카르복시 카노신 하이드로클로라이 0.1% 즉, 실시예 4를 처리한 후 자외선 조사에 대한 SOD 유사 활성을 나타냄.Irradiation 0.1%: Dicarboxy carnosine hydrochlory 0.1%, i.e. after treatment with Example 4 shows SOD-like activity against ultraviolet irradiation.
도 2에 나타난 바와 같이 자외선 조사를 하지 않았을 때는 0.1 O.D./min이었고 디카르복시 카노신 하이드로클로라이 0%에서는 0.17 O.D./min이었고 0.1%에서는 0.14 O.D./min로 공식에 의거하여 산정하면 약 43%의 보호효과를 나타내었다.As shown in FIG. 2, when the UV irradiation was not performed, 0.1 OD / min was 0.17 OD / min in 0% of dicarboxy carnosine hydrochlorine and 0.14 OD / min in 0.1%. It showed a protective effect.
실험예 3Experimental Example 3
주름개선 인체효능 시험Wrinkle improvement human efficacy test
1) 레플리카에 의한 이미지 분석1) Image analysis by replica
본 실험은 32세~55세의 여성 25명(평균 나이 42.3세)을 대상으로 12주 동안 실시하였다. 피부적응을 위해 1주일 동안은 하루에 한 번만 사용하게 했고, 그 다음부터는 하루 2회(아침, 저녁) 사용토록하였다. 피부 주름 레플리카는 실프로(Silflo; Flexico LTD.사제, 영국)를 사용하여 항온항습(22±2℃, 50±5% humidity)실에서 안정시킨 피험자의 눈꼬리쪽 부위의 주름 본을 떴다. 주름 레플리카 이미지 분석은 실온에서 본관된 사용 전, 6주, 12주 후의 레플리카에 약 38도의 빛을 조사하여 주름의 굴곡에 따른 그림자를 CCD 카메라로 찍어 주름의 깊이를 대신 측정하였다. 주름의 깊이를 측정하는 컴퓨터 영상 시스템은 C+K사의 Skin-Visiometer SV 600 software를 사용하여 분석하였다. 임의의 단위인 R1~R5 값 중 R1, R2, R3는 깊은 주름에 대한 값으로 3가지 변수 중에서 두 가지 이상의 변수가 유의성 있게 나올 경우 깊은 주름에 대하여 효능을 보이는 것으로 해석하였고, R4와 R5는 얕은 주름에 대한 값으로 R4나 R5 값 중 하나라도 유의성 있게 나올 경우 얕은 주름에 대하여 효능을 보이는 것으로 해석하였다.The study was conducted for 12 weeks with 25 women (mean age 42.3 years) aged 32-55 years. The skin was used only once a day for a week and then twice a day (morning and evening). The dermal wrinkle replica was made using Silflo (manufactured by Flexico, Inc., UK) to obtain a wrinkle pattern on the tail of the subject's eye area, which was stabilized in a constant temperature and humidity room (22 ± 2 ° C, 50 ± 5% humidity). For wrinkle replica image analysis, the replica was irradiated with light of about 38 degrees to the replica after 6 weeks and 12 weeks of use at room temperature, and the shadow of wrinkles was taken with a CCD camera to measure the depth of wrinkles instead. A computer imaging system for measuring wrinkle depth was analyzed using C + K's Skin-Visiometer SV 600 software. R1, R2, and R3 of arbitrary units, R1, R2, and R3, are values for deep wrinkles. When two or more variables among three variables are significant, they are interpreted as effective against deep wrinkles. R4 and R5 are shallow. When any one of the R4 or R5 value was found to be significant for wrinkles, it was interpreted as showing efficacy against shallow wrinkles.
R1 : 주름 등고선의 최고치와 최저치 차이값R1: difference between the highest and lowest of the wrinkle contour
R2 : 주름 동고선을 임의로 5칸씩 나눈 후 그 중 R1값들의 평균R2: Average of R1 values after randomly dividing 5 lines of wrinkles
R3 : 5개씩 나눈 R1값 중 최고치R3: Highest value of R1 divided by 5
R4 : 주름 등고선의 베이스라인에서 각각의 꼭대기와 계곡의 값을 뺀 평균값R4 is the mean value of the baseline of the wrinkle contour, minus the value of each top and valley.
상기 변수의 값이 작을수록 주름이 작음을 의미한다.The smaller the value of the variable, the smaller the wrinkles.
표 7은 실시예 3 을 12주동안 사용한 후 수평선(horizontal lines)을 기준으로 분석한 주름 레플리카 값에서 사용전 주름 레플리카 값을 뺀 △값을 표시한 것이고 independent t-test를 통해 제품군과 대조군 간의 유의성 여부를 생물학적 통계기준(p<0.05)으로 확인하였다.Table 7 shows the value of △ after subtracting the wrinkle replica value from the wrinkle replica value analyzed based on the horizontal lines after using Example 3 for 12 weeks, and the significance between the family and the control group through an independent t-test. Whether or not was confirmed by biological statistical criteria (p <0.05).
상기의 결과로부터 실시예 3 은 대조군과 비교하였을 때 깊은 주름 및 얕은 주름에서 유의한 수준의 주름 개선 효과를 나타냄을 확인할 수 있다.From the above results, it can be seen that Example 3 exhibits a significant level of wrinkle improvement in deep and shallow wrinkles when compared to the control group.
하기 표 8은 주름 분석 변수로 원형(circle)이 기준이었고 표 7과 마찬가지로 12주동안 사용한 후 측정한 △값을 표시하였다.Table 8 below was a circle (circle) as a criterion analysis parameter and used as shown in Table 7 for Δ value measured after 12 weeks.
상기의 결과로부터 실시예 3은 대조군과 비교하였을 때 깊은 주름 및 얕은 주름에서 유의한 수준의 주름 개선 효과를 나타냄을 확인할 수 있다.From the above results it can be seen that Example 3 shows a significant level of wrinkle improvement effect in the deep wrinkles and shallow wrinkles compared to the control group.
2) 임상 사진 촬영 및 육안 판정을 통한 주름개선 평가2) Evaluation of wrinkle improvement through clinical photography and visual judgment
25명의 피험자를 대상으로 피부과전문의 2인이 육안 평가를 실시하였다. 주름수치는 주름이 없는 '1'부터 주름이 많은 '13'까지의 정수로 기록하였다. 육안 주름 평가는 실시예3에 따른 제품 사용 전, 사용 6주 후, 사용 12주 후에 각각 측정하였고 사용후와 사용전에 대한 차이를 △값으로 표시하였다. independent t-test에 의해 유의수준 p<0.05에서 주름 개선 정도를 확인하였다.Twenty-five subjects were visually evaluated by two dermatologists. Wrinkle values were recorded as integers ranging from '1' without wrinkles to '13' with many wrinkles. Visual wrinkle evaluation was measured before use, after 6 weeks of use, and after 12 weeks of use according to Example 3, and the difference between after use and before use was expressed as Δ value. Independent t-test confirmed the improvement of wrinkles at the significance level p <0.05.
상기 결과에 따르면, 실시예3에 따른 제품 사용 6주 후에는 통계적으로 유의한 수준의 주름 개선 효과는 나타나지 않았으나, 제품 사용 12주 후에는 대조군과 비교하였을 때 통계적으로 유의한 주름개선 효과를 나타내었다.According to the above results, after 6 weeks of product use according to Example 3, there was no statistically significant level of wrinkle improvement, but after 12 weeks of use of the product, it showed statistically significant wrinkle improvement effect when compared to the control group. .
실험예 4Experimental Example 4
제품의 안전성 평가Product safety assessment
1) 설문을 통한 피험자 안전성 평가1) Evaluation of subject safety through questionnaire
실험예 3과 동일한 피험자 25명을 대상으로 설문 및 문진에 의한 실시예3에 따른 제품의 안전성 평가를 6주와 12주 후에 실시하였다.For 25 subjects as in Experimental Example 3, the safety evaluation of the product according to Example 3 by questionnaires and questionnaires was carried out after 6 and 12 weeks.
상기 표 10에서 알수 있는바와 같이 25명 모두가 설문에서 본 발명의 실시예3에 따른 제품의 지속적 사용으로 인한 피부자극을 경험하지 않은 것으로 파악되었고 피부과전문의 안전성 평가에서도 동일한 결과를 나타내었다.As can be seen in Table 10, all 25 people did not experience skin irritation due to the continuous use of the product according to Example 3 of the present invention in the questionnaire and showed the same result in the safety evaluation of dermatologists.
상기한 바와 같이 본 발명의 구성에 따라 디카르복시 카노신 하이드로 클로라이드를 함유한 화장료 조성물은 콜라겐의 합성을 증가시키고 항산화 작용을 가지고 있어 인체의 주름 형성을 방지 할 뿐 아니라, 피부에 대한 안전성이 우수하며, 화장료 조성물에서의 물질의 안정성도 우수하다.As described above, the cosmetic composition containing dicarboxy carnosine hydrochloride according to the composition of the present invention increases the synthesis of collagen and has an antioxidant action, which not only prevents the formation of wrinkles in the human body, but also has excellent safety for the skin. The stability of the substance in the cosmetic composition is also excellent.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030010259A KR20040074795A (en) | 2003-02-19 | 2003-02-19 | Cosmetic composition for preventing a wrinkles |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030010259A KR20040074795A (en) | 2003-02-19 | 2003-02-19 | Cosmetic composition for preventing a wrinkles |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20040074795A true KR20040074795A (en) | 2004-08-26 |
Family
ID=37361420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030010259A Ceased KR20040074795A (en) | 2003-02-19 | 2003-02-19 | Cosmetic composition for preventing a wrinkles |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20040074795A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105434285A (en) * | 2015-12-31 | 2016-03-30 | 天津达仁堂京万红药业有限公司 | Moisturizing and nourishing facial cream and preparation method thereof |
CN105434284A (en) * | 2015-12-31 | 2016-03-30 | 天津达仁堂京万红药业有限公司 | Moisturizing and nourishing eye serum and preparation method thereof |
CN105456141A (en) * | 2015-12-31 | 2016-04-06 | 天津达仁堂京万红药业有限公司 | Hydrating and nourishing mask and preparing method thereof |
WO2017101976A1 (en) * | 2015-12-15 | 2017-06-22 | Symrise Ag | Preparations comprising carnosines |
WO2024061476A1 (en) | 2022-09-19 | 2024-03-28 | Symrise Ag | A method for preventing, mitigating and/or treating ptgs2-induced skin disorders and related dysfunctions |
-
2003
- 2003-02-19 KR KR1020030010259A patent/KR20040074795A/en not_active Ceased
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017101976A1 (en) * | 2015-12-15 | 2017-06-22 | Symrise Ag | Preparations comprising carnosines |
CN108430448A (en) * | 2015-12-15 | 2018-08-21 | 西姆莱斯股份公司 | Lotion containing UV sun protection factors and carnosine |
US10857085B2 (en) | 2015-12-15 | 2020-12-08 | Symrise Ag | Preparations comprising carnosines |
CN108430448B (en) * | 2015-12-15 | 2021-10-01 | 西姆莱斯股份公司 | Emulsion containing UV sun protection factor and carnosine |
CN105434285A (en) * | 2015-12-31 | 2016-03-30 | 天津达仁堂京万红药业有限公司 | Moisturizing and nourishing facial cream and preparation method thereof |
CN105434284A (en) * | 2015-12-31 | 2016-03-30 | 天津达仁堂京万红药业有限公司 | Moisturizing and nourishing eye serum and preparation method thereof |
CN105456141A (en) * | 2015-12-31 | 2016-04-06 | 天津达仁堂京万红药业有限公司 | Hydrating and nourishing mask and preparing method thereof |
CN105456141B (en) * | 2015-12-31 | 2018-07-13 | 天津达仁堂京万红药业有限公司 | A kind of water profit nourishes facial mask and preparation method thereof |
CN105434284B (en) * | 2015-12-31 | 2019-01-22 | 天津达仁堂京万红药业有限公司 | A kind of moisturizing and nourishing eye essence and preparation method thereof |
WO2024061476A1 (en) | 2022-09-19 | 2024-03-28 | Symrise Ag | A method for preventing, mitigating and/or treating ptgs2-induced skin disorders and related dysfunctions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8221746B2 (en) | Antioxidant for use in cosmetic, medicated and pharmaceutical preparations | |
KR101517950B1 (en) | Cosmetic composition with mucus from sturgeon | |
JP2004501953A (en) | Use of creatine and / or creatine derivatives in cosmetic or dermatological preparations | |
US20040241197A1 (en) | Cosmetic or dermatological preparations including creatinine or a derivative thereof and creatine or a derivative thereof and methods of applying the preparations to the skin | |
KR101460669B1 (en) | Cosmetic composition with mucus from fish | |
JP2003063985A (en) | Composition for cosmetic or the skin containing elastase- inhibiting compound of n-acylaminoamido family and at least one anti-inflammatory compound | |
KR20010057661A (en) | Skin care composition containing retinol and epidermal growth factor | |
JP4454927B2 (en) | Cosmetic treatments using new retinoids | |
KR20040074795A (en) | Cosmetic composition for preventing a wrinkles | |
JP2004538299A (en) | Use of creatinine and / or creatinine derivatives in cosmetic and dermatological preparations | |
KR100478033B1 (en) | Composition having inhibitory effect on formation of skin wrinkle | |
KR20070082635A (en) | Skin external preparation containing red pine leaf extract | |
JP2534191B2 (en) | Whitening agent | |
KR100574850B1 (en) | Cosmetic composition containing synthetic palmitoylpentapeptide | |
KR100424726B1 (en) | Skin care cosmetic composition containing stabilized vitamin C and phytosphingosine | |
KR100415430B1 (en) | Cosmetic composition containing stabilized L-ascorbic acid | |
KR101145814B1 (en) | Composition for improving skin wrinkle | |
JP2020203930A (en) | Cosmetics | |
KR20150105550A (en) | Cosmetic composition comprising mucus extract from spawn | |
JP2998846B2 (en) | Whitening cosmetics | |
KR102832366B1 (en) | A Cosmetic composition for improving skin elasticity or dermal density through increased cell energy containing skin improvement containing spirulina extract | |
Duarte et al. | Vitamin C, gene expression and skin health | |
KR20120061311A (en) | Cosmetic Composition comprising Hispidulin or derivative thereof as an active ingredient | |
JPH0761919A (en) | Whitening agent | |
KR100364288B1 (en) | Skin care composition containing Epidermal Growth Factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20030219 |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20080218 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20030219 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20091124 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20100129 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20091124 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |